| Leila Ganjehei, MD | |
|
421 Epting Ave, Greenwood, SC 29646-4041 | |
| (864) 227-6818 | |
| (864) 227-0850 |
| Full Name | Leila Ganjehei |
|---|---|
| Gender | Female |
| Speciality | Cardiovascular Disease (cardiology) |
| Experience | 20 Years |
| Location | 421 Epting Ave, Greenwood, South Carolina |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1336436583 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | 247372 (Massachusetts) | Secondary |
| 207RC0000X | Internal Medicine - Cardiovascular Disease | 51440 (South Carolina) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Kaiser Foundation Hospital And Rehab Center | Vallejo, CA | Hospital |
| Kaiser Foundation Hosp So Sacramento | Sacramento, CA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Permanente Medical Group Inc | 8921910225 | 7800 |
News Archive
Discussing and documenting patients' preferences for care at the end of life does not cause them any harm, contrary to recent claims. A new study published today in the Journal of Hospital Medicine found that patients who talk with their physicians about end-of-life care and have an advance directive in their medical record have similar survival rates as patients who do not have these discussions and documents.
Amarin Corporation plc, a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today reported positive, statistically significant top-line results from the MARINE study, its first Phase 3 clinical trial of lead drug candidate AMR101.
In a continuing effort to serve the health care needs of medically underserved populations across Birmingham and the state of Alabama, the University of Alabama at Birmingham School of Nursing has long partnered with community agencies and facilities to identify and assist those who struggle most to receive proper health care by providing care through the school's nurse-managed clinics.
Stemedica Cell Technologies, Inc. (Stemedica), a world leader in stem cell research and manufacturing, announced that it has filed an Investigative New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for a clinical trial. The trial will assess the safety, tolerability and efficacy of Stemedica's high potency proprietary allogeneic mesenchymal bone marrow-derived stem cells (adult human) as a treatment for ischemic stroke.
The Alliance of Specialty Medicine, representing over 100,000 specialty physicians nationwide, released the following statement on Congress's unwillingness to improve and permanently fix the Medicare reimbursement system:
› Verified 5 days ago
| Entity Name | Permanente Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1073606299 PECOS PAC ID: 8921910225 Enrollment ID: O20031104000710 |
News Archive
Discussing and documenting patients' preferences for care at the end of life does not cause them any harm, contrary to recent claims. A new study published today in the Journal of Hospital Medicine found that patients who talk with their physicians about end-of-life care and have an advance directive in their medical record have similar survival rates as patients who do not have these discussions and documents.
Amarin Corporation plc, a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today reported positive, statistically significant top-line results from the MARINE study, its first Phase 3 clinical trial of lead drug candidate AMR101.
In a continuing effort to serve the health care needs of medically underserved populations across Birmingham and the state of Alabama, the University of Alabama at Birmingham School of Nursing has long partnered with community agencies and facilities to identify and assist those who struggle most to receive proper health care by providing care through the school's nurse-managed clinics.
Stemedica Cell Technologies, Inc. (Stemedica), a world leader in stem cell research and manufacturing, announced that it has filed an Investigative New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for a clinical trial. The trial will assess the safety, tolerability and efficacy of Stemedica's high potency proprietary allogeneic mesenchymal bone marrow-derived stem cells (adult human) as a treatment for ischemic stroke.
The Alliance of Specialty Medicine, representing over 100,000 specialty physicians nationwide, released the following statement on Congress's unwillingness to improve and permanently fix the Medicare reimbursement system:
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Leila Ganjehei, MD 421 Epting Ave, Greenwood, SC 29646-4041 Ph: (864) 227-6818 | Leila Ganjehei, MD 421 Epting Ave, Greenwood, SC 29646-4041 Ph: (864) 227-6818 |
News Archive
Discussing and documenting patients' preferences for care at the end of life does not cause them any harm, contrary to recent claims. A new study published today in the Journal of Hospital Medicine found that patients who talk with their physicians about end-of-life care and have an advance directive in their medical record have similar survival rates as patients who do not have these discussions and documents.
Amarin Corporation plc, a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today reported positive, statistically significant top-line results from the MARINE study, its first Phase 3 clinical trial of lead drug candidate AMR101.
In a continuing effort to serve the health care needs of medically underserved populations across Birmingham and the state of Alabama, the University of Alabama at Birmingham School of Nursing has long partnered with community agencies and facilities to identify and assist those who struggle most to receive proper health care by providing care through the school's nurse-managed clinics.
Stemedica Cell Technologies, Inc. (Stemedica), a world leader in stem cell research and manufacturing, announced that it has filed an Investigative New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for a clinical trial. The trial will assess the safety, tolerability and efficacy of Stemedica's high potency proprietary allogeneic mesenchymal bone marrow-derived stem cells (adult human) as a treatment for ischemic stroke.
The Alliance of Specialty Medicine, representing over 100,000 specialty physicians nationwide, released the following statement on Congress's unwillingness to improve and permanently fix the Medicare reimbursement system:
› Verified 5 days ago
Carlos M Manalich, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 115 Overland Dr, Greenwood, SC 29646 Phone: 864-227-6641 Fax: 864-229-3953 | |
Dr. Leonard Cheung Lim, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 105 Vinecrest Ct # 1000, Greenwood, SC 29646 Phone: 864-725-3350 Fax: 864-725-3351 | |
John Trimmer Hicks, MD Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 917 Bypass 225 S, Greenwood, SC 29646 Phone: 864-953-8002 Fax: 864-953-9690 | |
Thomas Manon Philip, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1325 Spring St, Greenwood, SC 29646 Phone: 864-725-4272 Fax: 864-725-4452 | |
Gordon R Wagler, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 104 Liner Dr, Greenwood, SC 29646 Phone: 864-227-1115 | |
Lincoln M Mcginnis, MD Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 1325 Spring St, Greenwood, SC 29646 Phone: 864-725-4111 | |
Darryl B Best, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1325 Spring St, Greenwood, SC 29646 Phone: 864-725-4272 Fax: 864-725-4452 |